← Back to headlines
Lilly and Novo Nordisk Shares Rise on FDA GLP-1 Compounding Proposal
Pharmaceutical companies Lilly and Novo Nordisk saw their stock prices increase following a proposal from the FDA to exclude GLP-1 receptor agonists from the compounding list.
30 Apr, 14:52 — 30 Apr, 14:52
Sources
Showing 1 of 1 sources
Related Stories
Busy Philipps Reveals She Underwent Surgery to Remove Rare Brain Tumor
22m ago
Closing Arguments Set as Murder Trial of Chris Benoit Nears Conclusion
27m ago
Eight-Year-Old Boy Dies After Electric Shock From Water Cooler in UAE
31m ago
FDA Grants Expedited Approval to Revolutionary Pancreatic Cancer Drug
43m ago